Topic
Gabexate
About: Gabexate is a research topic. Over the lifetime, 150 publications have been published within this topic receiving 3708 citations. The topic is also known as: Gabexate.
Papers published on a yearly basis
Papers
TL;DR: The results show that gabexate mesilate was not effective in preventing complications and mortality in acute pancreatitis, and the effect of high doses of the low molecular weight protease inhibitor gabExate Mesilate on mortality and complications associated with moderate and severe acute Pancreatitis.
220 citations
TL;DR: The pancreatic injury after ERCP can be prevented with the administration of either somatostatin or gabexate mesilate, but the former agent is more cost-effective.
207 citations
TL;DR: Injection of nontoxic doses of CCK-8 before proglumide or gabexate injections completely abolished all beneficial effects and also increased the severity of pancreatitis due to CDE diet alone.
Abstract: The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet. Injections of gabexate and proglumide from initiation of CDE diet (before induction of pancreatitis) increased survival from 37% (diet alone) to 85 and 75%, respectively, and also ameliorated histological alterations and increases in serum amylase concentration and pancreatic activated trypsin. Secretin had no major beneficial effect. When proglumide or gabexate were given after induction of pancreatitis, proglumide still increased survival to 75%, whereas gabexate no longer did. Injection of nontoxic doses of CCK-8 before proglumide or gabexate injections completely abolished all beneficial effects and also increased the severity of pancreatitis due to CDE diet alone. Blockade of CCK receptors and early inhibition of protease activity may be beneficial in severe acute pancreatitis. Cholecystokinin appears to play a contributory role in the development of pancreatitis.
176 citations
TL;DR: Short- or long-term infusion of SS or GM proved ineffective in reducing post-ERCP pancreatitis and pain and when given as a bolus injection, SS maintains its promise in this field, but additional data are needed.
136 citations
TL;DR: Data strongly support that FUT-175 is clinically useful in the therapy of acute pancreatitis and reduces the mortality of rats in the experimental acute pancreas in a dose-dependent manner.
114 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2020 | 3 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 3 |